“Stay on top of the evidence base” — Adeera Levin on WCN’26 HIT sessions
At WCN’26, the high-impact trials (HIT) and late-breaking clinical trials (LBCT) sessions will show you what matters most for patient care right now. From headline results to ongoing studies, attendees will gain insights to translate evidence into better clinical decisions.
Adeera Levin, chair of both the ISN–Advancing Clinical Trials Committee and the WCN’26 LBCT Advisory Group, explains that these sessions highlight the clinical trials most impactful to kidney care professionals, “This helps all of us as a community stay on top of the evidence base needed to care for our patients,” she adds.
In addition to presenting key results from major studies, ongoing trials will also be explored. As Professor Levin notes, “Ongoing research helps the kidney care community to understand better what is being studied and why, so that when presented, the results can be more readily incorporated into clinical practice.”
The sessions also offer a window into innovative study designs and emerging therapies that will define future kidney research. “Ensuring that nephrologists everywhere are aware of the clinical trial landscape, and have an improved understanding of trial designs, methods, and rationale, will help to both care for patients in the moment, and also shape the culture of kidney care to be more inclusive of all patients,” Professor Levin emphasizes.
Here’s what’s in store at the HIT sessions:
HIT! High-impact Clinical Trials 1
Flagship late-breaking trials, including major studies, such as the REMODEL Trial and Phase III Global Multicenter Inshore Trial, with presentation of headline results and clinical implications.
HIT! High-impact Clinical Trials 2
New insights from ongoing analyses, including ASPIRE, RESOLVE, and VOICE, offer deeper interpretations of trial data and their implications for patient care.
HIT! High-impact Clinical Trials 3
A focused session on IgA nephropathy, featuring key studies, including APPLAUSE, addressing disease mechanisms, treatment strategies, and outcomes.
HIT! High-impact Clinical Trials 4
Trials in progress, including the TICKERS_HD study and the CONFIDENCE trial, highlight emerging therapies, innovative study designs, and research questions that will define the next phase of kidney research.
Engage with the studies driving change in kidney care at the HIT/LBCT sessions at WCN’26!
